CCAT2 and breast cancer: Although, CCAT2 is overall overexpressed in BCs in two out of three patients sets, having the highest expression in LNN disease, its expression levels are clinically informative solely for a subgroup of BC patients, namely for patients with LNP disease that have received adjuvant CMF chemotherapy.